| Date | Time | Source | |
| 04/18/2024 | 7:10AM | BW | Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893... More...>> |
| 04/07/2024 | 4:30PM | BW | Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families. The findings of this study, which identified a significant discrepancy... More...>> |
| 03/11/2024 | 2:00PM | BW | Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A study of Edwards’ latest... More...>> |
| 02/23/2024 | 7:05AM | BW | Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available... More...>> |
| 02/06/2024 | 4:15PM | BW | Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64... More...>> |
| 02/02/2024 | 7:00AM | BW | Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health... More...>> |
| 01/30/2024 | 7:05AM | BW | Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893... More...>> |
| 01/02/2024 | 9:00AM | BW | Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast... More...>> |
| 12/07/2023 | 8:30AM | BW | Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference. Highlights of today’s conference include: Expecting early completion of... More...>> |
| 11/28/2023 | 7:06AM | IHMARKETNEWS | Keep An Eye Out: Pre-Market Movers And Analyst Recommendations
Today, all eyes are focused on U.S. CB consumer confidence data in a couple of hours. Economists, on average, forecast that November CB Consumer Confidence will stand at 101.0, compared to the previous figure of 102.6. Also, investors will likely focus on the U.S. S&P/CS HPI composite – 20 n.s.a, which came in... More...>> |
| 10/26/2023 | 3:06PM | PRNUS | CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION PR Newswire SAN FRANCISCO, Oct. 26, 2023 SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled... More...>> |
| 10/26/2023 | 2:00PM | PRNUS | TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION PR Newswire SAN FRANCISCO, Oct. 26, 2023 SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results... More...>> |
| 10/25/2023 | 4:15PM | PRNUS | EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS PR Newswire IRVINE, Calif., Oct. 25, 2023 IRVINE, Calif., Oct. 25, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook Q3 sales grew 12 percent to $1.48 billion; constant... More...>> |
| 10/24/2023 | 2:00PM | PRNUS | FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE
FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE PR Newswire SAN FRANCISCO, Oct. 24, 2023 SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause... More...>> |
| 10/19/2023 | 8:30AM | PRNUS | EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK PR Newswire IRVINE, Calif., Oct. 19, 2023 IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter... More...>> |
| 10/18/2023 | 7:05AM | PRNUS | EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023 PR Newswire IRVINE, Calif., Oct. 18, 2023 IRVINE, Calif., Oct. 18, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on Wednesday, October... More...>> |
| 09/08/2023 | 10:08AM | IHMARKETNEWS | Keep An Eye Out: Pre-Market Movers And Recommendations
Adobe (NASDAQ:ADBE): Barclays maintains its equalweight rating with a target price raised from $540 to $620. Docusign (NASDAQ:DOCU): Morgan Stanley maintains its underweight recommendation with a target price increase from $49 to $51. Edwards Life (NYSE:EW): Piper Sandler & Co maintains a neutral recommendation on... More...>> |
| 08/28/2023 | 8:10AM | PRNUS | EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE PR Newswire IRVINE, Calif., Aug. 28, 2023 IRVINE, Calif., Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September... More...>> |
| 08/02/2023 | 11:58AM | DJN | Correction to Edwards Lifesciences 2Q Net Headline on July 26
Edwards Lifesciences posted second-quarter net income of $307.1 million. "*Edwards Lifesciences 2Q Net $305.5M >EW," at 4:15 p.m. ET July 26, incorrectly stated the net as $305.5 million. (END) Dow Jones Newswires August 02, 2023 11:43 ET (15:43 GMT) Copyright (c) 2023 Dow Jones & Company, Inc. More...>> |
| 07/26/2023 | 4:15PM | PRNUS | EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS
EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS PR Newswire IRVINE, Calif., July 26, 2023 IRVINE, Calif., July 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent to $1.53 billion; constant currency1... More...>> |